Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
5 c » 25 c (Expand Search)
Showing 921 - 940 results of 73,733 for search '(( 5 c decrease ) OR ( 5 ((((step decrease) OR (we decrease))) OR (nn decrease)) ))', query time: 1.48s Refine Results
  1. 921
    Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure

    Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure by Wei Meng (505670)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  2. 922
    D-4F and L-5F attenuate hepatic triglyceride accumulation.

    D-4F and L-5F attenuate hepatic triglyceride accumulation. by Kristine C. McGrath (8269155)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  3. 923
    S5 Fig -

    S5 Fig - by David Mathar (9707947)

    Published 2022
    Save to List
    Saved in:
  4. 924
    Values for vertical foot clearance, foot overhang, anteroposterior MoS and mediolateral MoS on steps 4, 5 and 6 across conditions.

    Values for vertical foot clearance, foot overhang, anteroposterior MoS and mediolateral MoS on steps 4, 5 and 6 across conditions. by Timmion K. Skervin (11432568)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  5. 925
    Table_3_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.pdf

    Table_3_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  6. 926
    Image_2_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.png

    Image_2_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  7. 927
    Table_1_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.pdf

    Table_1_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  8. 928
    Table_3_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.pdf

    Table_3_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  9. 929
    Table_1_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.pdf

    Table_1_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  10. 930
    Table_2_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.pdf

    Table_2_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  11. 931
    Table_2_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.pdf

    Table_2_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  12. 932
    Image_1_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.png

    Image_1_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  13. 933
    Image_1_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.png

    Image_1_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  14. 934
    Image_2_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.png

    Image_2_Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Th... by Yingying Yu (546494)

    Published 2022
    Save to List
    Saved in:
  15. 935
    Image5_PKA inhibition is a central step in D,L-methadone-induced ER Ca2+ release and subsequent apoptosis in acute lymphoblastic leukemia.JPEG

    Image5_PKA inhibition is a central step in D,L-methadone-induced ER Ca2+ release and subsequent apoptosis in acute lymphoblastic leukemia.JPEG by Hamza Kamran (18433152)

    Published 2024
    Save to List
    Saved in:
  16. 936
    mGluR-interacting domains on PrP<sup>C</sup>.

    mGluR-interacting domains on PrP<sup>C</sup>. by Despoina Goniotaki (4167256)

    Published 2017
    “…For detection, we used polyclonal antibodies to mGluR5, mGluR1, and PrP<sup>C</sup>. …”
    Save to List
    Saved in:
  17. 937
    Genome-wide occurrence of 5mC and SNPs in Zt10.

    Genome-wide occurrence of 5mC and SNPs in Zt10. by Mareike Möller (5548745)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  18. 938
    Numerical data values for Figs 2B, 3C, 3D, 4B, 4C, 5A, 5B, 5C, 5D, 6D, 6F, 8A, 8B, 8C, 8D, 9D and 9E.

    Numerical data values for Figs 2B, 3C, 3D, 4B, 4C, 5A, 5B, 5C, 5D, 6D, 6F, 8A, 8B, 8C, 8D, 9D and 9E. by Shweta Singh (409313)

    Published 2022
    Save to List
    Saved in:
  19. 939
    5-Aza-2-deoxycytidine (5-Aza-dC) treatment does not affect methylation status of the CpG islands near to putative promoter region of both genes.

    5-Aza-2-deoxycytidine (5-Aza-dC) treatment does not affect methylation status of the CpG islands near to putative promoter region of both genes. by Bruna Rodrigues Muys (2588305)

    Published 2016
    Save to List
    Saved in:
  20. 940
    Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus

    Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus by Marie-Laure Plissonnier (337713)

    Published 2016
    “…<div><p>Hepatitis C virus (HCV) is an oncogenic virus associated with the onset of hepatocellular carcinoma (HCC). …”
    Save to List
    Saved in:

Search Tools: